These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37918792)

  • 1. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
    Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
    J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth.
    Miao X; Shen S; Koch G; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
    J Pharm Sci; 2024 Jan; 113(1):214-227. PubMed ID: 38498417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
    Miao X; Koch G; Straubinger RM; Jusko WJ
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):181-93. PubMed ID: 26604207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
    Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.
    Miao X; Koch G; Ait-Oudhia S; Straubinger RM; Jusko WJ
    Front Pharmacol; 2016; 7():421. PubMed ID: 27895579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
    Hamed SS; Straubinger RM; Jusko WJ
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):553-63. PubMed ID: 23835677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
    Zhu X; Straubinger RM; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):477-96. PubMed ID: 26252969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.
    Niu J; Wang X; Qu J; Mager DE; Straubinger RM
    BMC Cancer; 2020 Oct; 20(1):1024. PubMed ID: 33097020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
    Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
    CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):549-561. PubMed ID: 30084546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
    Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
    Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
    BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
    Fiorini C; Cordani M; Padroni C; Blandino G; Di Agostino S; Donadelli M
    Biochim Biophys Acta; 2015 Jan; 1853(1):89-100. PubMed ID: 25311384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
    Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
    J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.
    Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ
    Front Pharmacol; 2018; 9():84. PubMed ID: 29520231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
    Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
    Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
    Lin Q; Shen S; Qian Z; Rasam SS; Serratore A; Jusko WJ; Kandel ES; Qu J; Straubinger RM
    Mol Cell Proteomics; 2022 Oct; 21(10):100409. PubMed ID: 36084875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
    Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
    J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.